Cerebral Vasospasm (CVS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Cerebral Vasospasm (CVS) Market Outlook
Thelansis’s “Cerebral Vasospasm (CVS) Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Cerebral Vasospasm (CVS) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Cerebral
Vasospasm (CVS) Overview
Cerebral
Vasospasm (CVS) is characterized by the narrowing of blood vessels in the
brain, resulting in decreased blood flow and subsequent brain tissue damage.
The Circle of Willis, located at the base of the brain and connecting its major
arteries, is frequently affected. This condition commonly arises following a
subarachnoid hemorrhage, which occurs when an aneurysm ruptures, leading to
bleeding around the brain. CVS affects approximately 75% of individuals who
survive such hemorrhages, although only about 30% experience symptomatic
cognitive deficits. Intracranial arterial constriction typically emerges
several days after an aneurysm rupture and persists for 2 to 3 weeks. Our
research has shown that symptomatic vasospasm is linked to diminished cognitive
function and reduced quality of life, though not necessarily to death or severe
disability. Delayed cerebral ischemia (DCI) appears to be the most
comprehensive and clinically relevant definition for capturing the adverse
consequences of vasospasm following subarachnoid hemorrhage. Once diagnosed,
treatment options for CVS include elevating blood pressure to enhance brain
perfusion and performing angiography. Depending on the severity and location of
the vasospasm, physicians may administer medication directly into the affected
arteries via angiography or perform balloon angioplasty to widen the narrowed
vessels. Cerebral Vasospasm has been estimated to occur in approximately 50% of
patients with aneurysmal subarachnoid hemorrhage (aSAH), a condition affecting
around 40,000 individuals in North America annually. Symptomatic vasospasm,
occurring in 16% of patients, is accompanied by delayed cerebral ischemia in
21%, angiographic vasospasm in 31%, and transcranial Doppler (TCD) spasm in 45%
of cases.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment